10x Genomics, Inc.
TXG
株式のランク
#2179
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012... Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
株価
$72.10
最終同期: 2026-10-20
時価総額
$9.39B
変化（1日）
3.16%
変化（1年）
453.34%
国
US
取引 10x Genomics, Inc. (TXG)
カテゴリー
Healthcare
10x Genomics, Inc.（TXG）の収益
Jun 2026 時点の収益 TTM: $616.91M
10x Genomics, Inc. の最新の財務報告によると、現在の収益 (TTM) は $616.91M です。2024 年には $610.79M の収益があり、これは 2023 年の $618.73M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
10x Genomics, Inc. の収益履歴（2017 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $616.91M | -4.03% |
| 2025 | $642.82M | 5.25% |
| 2024 | $610.79M | -1.28% |
| 2023 | $618.73M | 19.81% |
| 2022 | $516.41M | 5.28% |
| 2021 | $490.49M | 64.13% |
| 2020 | $298.85M | 21.53% |
| 2019 | $245.89M | 68.06% |
| 2018 | $146.31M | 105.83% |
| 2017 | $71.09M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $20.24B | 3,181.35% |
US
|
|
| $184.56M | -70.08% |
AU
|
|
| $14.37B | 2,229.61% |
US
|
|
| $1.43B | 132.13% |
US
|
|
| - | - |
US
|
